Crystalline forms of squalamine

1 . A crystalline phosphate hydrate of Compound I:

wherein the crystalline phosphate hydrate comprises Form A1 and/or Form C, wherein:

a) Form A1 is characterized by an X-ray powder diffraction (XRPD) pattern having peaks (Cu K α1 radiation) at 3.96°, 8.59°, 10.84°, 11.49°, 13.27°, 13.89°, 15.27°, 15.52°, 15.78°, 15.98°, 17.72°, 17.91°, 18.76°, 19.18°, 19.37°, 20.44°, 20.58°, 20.80°, 21.24°, 21.76°, 22.18°, 23.09°, 23.35°, 23.83°, 24.02°, 24.53°, 25.10°, 25.48°, 25.81°, 26.14°, and 26.67° (each ±0.01°2θ); and

b) Form C is characterized by an X-ray powder diffraction (XRPD) pattern having peaks (Cu K α1 radiation) at 3.82°, 8.22°, 10.55°, 11.19°, 11.45°, 11.99°, 13.35°, 13.77°, 14.05°, 14.59°, 15.14°, 15.63°, 16.39°, 16.89°, 17.28°, 17.94°, 18.57°, 18.92°, 19.39°, 19.75°, 20.71°, 21.16°, 21.45°, 21.99°, 22.49°, 22.98°, 23.26°, 23.79°, 24.11°, 24.59°, and 24.91° (each ±0.01°2θ).

2 . The crystalline phosphate hydrate of claim 1 :

wherein the crystalline phosphate hydrate comprises Form A1; and wherein:

(a) the crystalline phosphate hydrate is a tetrahydrate; and/or

(b) has a differential scanning calorimetry thermogram comprising an endotherm at about 40° C. to about 120° C.

3 . The crystalline phosphate hydrate of claim 1 :

wherein the crystalline phosphate hydrate comprises Form C; and wherein:

(a) the crystalline phosphate hydrate is a hexahydrate; and/or

(b) has a differential scanning calorimetry thermogram comprising an endotherm at about 40° C. to about 120° C.

4 . A composition comprising the crystalline phosphate hydrate of claim 1 .

5 . The composition of claim 4 , comprising one or more of the following:

(a) an aqueous carrier;

(b) a buffer;

(c) a sugar; and/or

(d) a polyol compound.

6 . The composition of claim 4 , wherein the composition further comprises at least one additional active agent.

7 . The composition of claim 4 , wherein the composition is formulated:

(a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, intravenous, subcutaneous, intramuscular, nebulization, inhalation, ocular, otic, local, buccal, nasal, and topical administration;

(b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, and capsules;

(c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or

(d) any combination of (a), (b), and (c).

8 . The composition of claim 4 , formulated:

(a) for oral administration; and/or

(b) as an oral tablet or capsule; and/or

(c) for intranasal administration.

9 . A method of preparing the crystalline phosphate hydrate of claim 1 , comprising contacting Compound II:

or a pharmaceutically acceptable salt thereof, with phosphoric acid to form the crystalline phosphate hydrate.

10 . The method of claim 9 , wherein the pharmaceutically acceptable of Compound II is a lactate salt of Compound II.

11 . The method of claim 10 , wherein the lactate salt of Compound II has the formula:

12 . The method of claim 9 , wherein:

(a) Compound II, or a pharmaceutically acceptable salt thereof, is in water and ethanol prior to contacting with phosphoric acid; and/or

(b) the ratio of water to ethanol is about 1 to about 1; and/or

(c) the water and ethanol further comprise sodium hydroxide (NaOH).

13 . A method of treating a subject in need having a condition susceptible to treatment with an aminosterol, comprising administering a therapeutically effective amount of the composition according to claim 4 , and optionally wherein the condition is correlated with abnormal alpha-synuclein pathology and/or dopaminergic dysfunction.

14 . A method of treating, preventing, and/or slowing the onset or progression of a condition or disorder, or a related symptom, correlated with abnormal alpha-synuclein pathology and/or dopaminergic dysfunction, in a subject in need, comprising administering a therapeutically effective amount of a composition according to claim 4 .

15 . The method of claim 14 , wherein:

(a) the symptom is selected from the group consisting of constipation, hallucinations, cognitive impairment, and inflammation;

(b) the symptom is correlated with a synucleopathy, a neurodegenerative disease, a neurological disease or disorder, a psychological and/or behavior disorder, or a cerebral or general ischemic disorder or condition; or

(c) the condition or disorder is a synucleopathy, neurodegenerative disease, or neurological disease or disorder;

(d) the condition or disorder is a psychological and/or behavior disorder; or

(e) the condition or disorder is a cerebral or general ischemic disorder or condition.

16 . The method of claim 15 , wherein:

(a) the synucleopathy, neurodegenerative disease, or neurological disease or disorder is selected from the group consisting of Parkinson's disease, Alzheimer's disease, schizophrenia, multiple system atrophy, Lewy body dementia, dementia with Lewy bodies, Huntington's Disease, Multiple Sclerosis, Amyotorphic Lateral Sclerosis, Friedreich's ataxia, vascular dementia, spinal muscular atrophy, supranuclear palsy, progressive nuclear palsy, frontotemporal dementia, progressive nuclear palsy, Guadeloupian Parkinsonism, spinocerebellar ataxia, parkinsonism, traumatic brain injury, degenerative processes associated with aging, and dementia of aging;

(b) the psychological or behavior disorder is selected from the group consisting of depression, autism, autism spectrum disorder, Down syndrome, Gaucher's disease, Krabbe's disease, lysosomal conditions affecting glycosphingolipid metabolism, ADHD, agitation, anxiety, delirium, irritability, illusion and delusions, amnesia, apathy, bipolar disorder, disinhibition, aberrant motor and obsessive-compulsive behaviors, addiction, cerebral palsy, epilepsy, major depressive disorder, and sleep disorders such as REM sleep behavior disorder (RBD), sleep fragmentation, REM behavior disorder, circadian rhythm dysfunction, sleep apnea, and cognitive impairment; or

(c) the cerebral or general ischemic disorder or condition is selected from the group consisting of microangiopathy, intrapartum, cerebral ischemia, cerebral ischemia during/after cardiac arrest or resuscitation, cerebral ischemia due to intraoperative problems, cerebral ischemia during carotid surgery, chronic cerebral ischemia due to stenosis of blood-supplying arteries to the brain, sinus thrombosis or thrombosis of cerebral veins, cerebral vessel malformations, diabetic retinopathy, high cholesterol, myocardial infarction, cardiac insufficiency, cardiac failure, congestive heart failure, myocarditis, pericarditis, perimyocarditis, coronary heart disease, angina pectoris, congenital heart disease, shock, ischemia of extremities, stenosis of renal arteries, diabetic retinopathy, thrombosis associated with malaria, artificial heart valves, anemias, hypersplenic syndrome, emphysema, lung fibrosis, erectile dysfunction, cardiac conduction defects, high blood pressure, low blood pressure, and pulmonary edema.

17 . A method of treating, preventing, and/or slowing the onset or progression of a cerebral or general ischemic disorder and/or a related symptom, correlated with abnormal alpha-synuclein pathology and/or dopaminergic dysfunction, in a subject in need, comprising administering a therapeutically effective amount of a composition according to claim 4 .

18 . The method of claim 17 , wherein the cerebral or general ischemic disorder and/or a related symptom is selected from the group consisting of microangiopathy, intrapartum cerebral ischemia, cerebral ischemia during/after cardiac arrest or resuscitation, cerebral ischemia due to intraoperative problems, cerebral ischemia during carotid surgery, chronic cerebral ischemia due to stenosis of blood-supplying arteries to the brain, sinus thrombosis or thrombosis of cerebral veins, cerebral vessel malformations, diabetic retinopathy, high blood pressure, low blood pressure, high cholesterol, myocardial infarction, cardiac insufficiency, cardiac failure, congestive heart failure, myocarditis, pericarditis, perimyocarditis, coronary heart disease, angina pectoris, congenital heart disease, shock, ischemia of extremities, stenosis of renal arteries, diabetic retinopathy, thrombosis associated with malaria, artificial heart valves, anemias, hypersplenic syndrome, emphysema, lung fibrosis, erectile dysfunction, cardiac conduction defects (CCDs) and/or a related symptom, and pulmonary edema.

19 . A method of inhibiting protein tyrosine phosphatase 1B (PTP1B) in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition according to claim 4 .

20 . The method of claim 13 , wherein:

(a) the method of administration comprises oral, nasal, sublingual, buccal, rectal, vaginal, intravenous, intra-arterial, intradermal, intraperitoneal, intrathecal, intramuscular, epidural, intracerebral, intracerebroventricular, transdermal, or any combination thereof, and/or

(b) the method of administration is nasal administration, oral administration, or a combination thereof.

21 . The method of claim 13 , wherein:

(a) the therapeutically effective amount of the composition comprises:

(i) about 0.1 to about 20 mg/kg body weight of the subject;

(ii) about 0.1 to about 15 mg/kg body weight of the subject;

(iii) about 0.1 to about 10 mg/kg body weight of the subject;

(iv) about 0.1 to about 5 mg/kg body weight of the subject; or

(v) about 0.1 to about 2.5 mg/kg body weight of the subject; and/or

(b) the therapeutically effective amount of the composition comprises:

(i) about 0.001 to about 500 mg/day;

(ii) about 0.001 to about 250 mg/day;

(iii) about 0.001 to about 125 mg/day;

(iv) about 0.001 to about 50 mg/day;

(v) about 0.001 to about 25 mg/day;

(vi) about 0.001 to about 10 mg/day;

(vii) about 0.001 to about 6 mg/day;

(viii) about 0.001 to about 4 mg/day; or

(ix) about 0.001 to about 2 mg/day; and/or

(c) the method of administration comprises oral administration and wherein the therapeutically effective amount of the composition comprises:

(i) about 1 to about 300 mg/day; or

(ii) about 25 to about 500 mg/day.

22 . The method of claim 13 , wherein:

(a) the composition is administered in combination with at least one additional active agent to achieve either an additive or synergistic effect; and/or

(b) the composition is administered in combination with at least one additional active agent to achieve either an additive or synergistic effect and wherein the additional active agent is administered via a method selected from the group consisting of:

(i) concomitantly;

(ii) as an admixture;

(iii) separately and simultaneously or concurrently; and

(iv) separately and sequentially; and/or

(c) the composition is administered in combination with at least one additional active agent to achieve either an additive or synergistic effect, and wherein the additional active agent is a second aminosterol having a different structure from Compound I.

23 . The method of claim 13 , wherein:

(a) administration of the composition comprises administration on an empty stomach, optionally within two hours of the subject waking; and/or

(b) no food is consumed by the subject after about 60 to about 90 minutes from administration of the composition.

24 . The method of claim 13 , wherein the composition comprises a pharmaceutically acceptable grade of the crystalline phosphate hydrate of Compound I.

25 . The method of claim 13 , wherein the subject is a mammal, and optionally wherein the subject is a human.

26 . The method of claim 13 , further comprising:

(a) determining a dosage of the composition for the subject, wherein the composition dosage is determined based on the effectiveness of the composition dosage in improving or resolving a symptom being evaluated,

(b) followed by administering the composition dosage to the subject for a period of time, wherein the method comprises:

(i) identifying a symptom to be evaluated, wherein the symptom is susceptible to treatment with an aminosterol;

(ii) identifying a starting dosage of composition for the subject; and

(iii) administering an escalating composition dosage to the subject over a period of time until an effective dosage for the symptom being evaluated is identified, wherein the effective dosage is composition dosage where improvement or resolution of the symptom is observed, and fixing the composition dosage at that level for that particular symptom in that particular subject, and

optionally wherein improvement or resolution of the symptom is measured using a clinically recognized scale or tool.

27 . The method of claim 26 , wherein:

(a) the composition is administered orally and:

(i) the starting composition dosage ranges from about 10 mg up to about 150 mg/day;

(ii) the dosage of the composition for the subject following escalation is fixed at a range of from about 25 mg up to about 500 mg/day; and/or

(iii) the dosage of composition is escalated in about 25 mg increments; or

(b) the composition is administered intranasally and:

(i) the starting composition dosage ranges from about 0.001 mg to about 3 mg/day;

(ii) the dosage of the composition for the subject following escalation is fixed at a range of from about 0.001 mg up to about 6 mg/day;

(iii) the dosage of the composition for the subject following escalation is a dosage which is subtherapeutic when given orally or by injection; and/or

(iv) the dosage of the composition is escalated in increments of about 0.1, about 0.2, about 0.25, about 0.3, about 0.35, about 0.4, about 0.45, about 0.5, about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, about 0.8, about 0.85, about 0.9, about 0.95, about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2 mg.

28 . The method of claim 26 , wherein:

(a) the dosage of the composition is escalated every about 3 to about 5 days; and/or

(b) the starting composition dosage is higher if the symptom being evaluated is severe; and/or

(c) the symptom is correlated with abnormal alpha-synuclein pathology and/or dopaminergic dysfunction; and/or

(d) the symptom to be evaluated is selected from the group consisting of:

(i) at least one non-motor aspect of experiences of daily living as defined by Part I of the Unified Parkinson's Disease Rating Scale selected from the group consisting of cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, features of dopamine dysregulation syndrome, sleep problems, daytime sleepiness, pain, urinary problems, constipation problems, lightheadedness on standing, and fatigue;

(ii) at least one motor aspect of experiences of daily living as defined by Part II of the Unified Parkinson's Disease Rating Scale selected from the group consisting of speech, saliva and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, turning in bed, tremors, getting out of a bed, a car, or a deep chair, walking and balance, and freezing;

(iii) at least one motor symptom identified in Part III of the Unified Parkinson's Disease Rating Scale selected from the group consisting of speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, body bradykinesia, postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, and constancy of rest tremor;

(iv) at least one motor complication identified in Part IV of the Unified Parkinson's Disease Rating Scale selected from the group consisting of time spent with dyskinesias, functional impact of dyskinesias, time spent in the off state, functional impact of fluctuations, complexity of motor fluctuations, and painful off-state dystonia;

(v) constipation;

(vi) depression;

(vii) cognitive impairment;

(viii) sleep problems or sleep disturbances;

(ix) circadian rhythm dysfunction;

(x) hallucinations;

(xi) fatigue;

(xii) REM disturbed sleep;

(xiii) REM behavior disorder;

(xiv) erectile dysfunction;

(xv) apnea;

(xvi) postural hypotension;

(xvii) correction of blood pressure or orthostatic hypotension;

(xviii) nocturnal hypertension;

(xix) regulation of temperature;

(xx) improvement in breathing or apnea;

(xxi) correction of cardiac conduction defect;

(xxii) amelioration of pain;

(xxiii) restoration of bladder sensation and urination;

(xxiv) urinary incontinence; and/or

(xxv) control of nocturia.

29 . The method of claim 28 , wherein the symptom to be evaluated is constipation, and wherein:

(a) the fixed escalated composition dosage for constipation is defined as the composition dosage that results in a complete spontaneous bowel movement (CSBM) within 24 hours of dosing on at least 2 of 3 days at a given dosage;

(b) if average complete spontaneous bowel movement (CSBM) or average spontaneous bowel movement (SBM) is greater than or equal to 1 per week, then the starting composition dosage prior to escalation is 75 mg/day; and/or

(c) if average CSBM or SBM is less than 1 per week, then the starting composition dosage prior to escalation is 150 mg/day.

30 . A method of increasing gene transcription in the gut of a subject, comprising administering to the subject a therapeutically effective amount of a crystalline phosphate hydrate according to claim 1 .

31 . The method of claim 30 , wherein:

(a) the increase in gene transcription is for one or more genes selected from the group consisting of caspase 14, collagen type XVII alpha 1, corneodesmosin, cornifelin, cystatin E/M, dermokine, desmocollin 1, desmoglein 1 beta, filaggrin, gap junction protein beta 4, gap junction protein beta 6, H19 imprinted maternally expressed transcript, hornerin, kallikrein related-peptidase 7 chymotryptic stratum, keratin 1, keratin 10, keratinocyte differentiation associated protein, keratinocyte expressed proline-rich, late cornified envelope 1A1, late cornified envelope 1A2, late cornified envelope 1B, late cornified envelope 1C, late cornified envelope 1E, late cornified envelope 1F, late cornified envelope 1G, late cornified envelope 1H, late cornified envelope 1I, late cornified envelope 1J, late cornified envelope 1L, late cornified envelope 1M, late cornified envelope 3C, late cornified envelope 3E, late cornified envelope 3F, lectin galactose binding soluble 7, loricrin, sciellin, myoglobin, myosin binding protein C slow-type, myosin heavy polypeptide 1 skeletal muscle, myosin heavy polypeptide 8 skeletal muscle, myosin light chain phosphorylatable fast ske, myosin light polypeptide 3, myozenin 1, myozenin 2, and titin-cap; and/or

(b) the increase in gene transcription is selected from about 1% to about 10%, about 10% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, about 60% to about 70%, about 70% to about 80%, about 80% to about 90%, about 90% to about 100%, about 100% to about 125%, about 125% to about 150%, about 150% to about 175%, about 175% to about 200%, about 200% to about 250%, about 250% to about 300%, about 300% to about 350%, about 350% to about 400%, about 400% to about 450%, about 500% to about 600%, about 600% to about 700%, about 700% to about 800%, about 800% to about 900%, about 900% to about 1000%, or about 1000% to about 1500%.